Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Multi-Center, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

Next Previous
Trial Profile

A Phase 1/2, Multi-Center, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Elotuzumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 15 Jan 2018 Results of pooled data from five trials assessing role of elotuzumab in the treatment of relapsed or refractory multiple myeloma, were published in the American Journal of Health-System Pharmacy.
  • 27 Feb 2012 Planned number of patients changed from 49 to 60 as reported by ClinicalTrials.gov.
  • 27 Feb 2012 Planned End Date changed from 1 Sep 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top